US Patent 11,998,565 scope and claims analysis: injectable selenium composition with controlled trace metals and fluoride/iodine for parenteral nutrition
US 11,998,565 claims a narrow class of injectable formulations defined by (i) selenium dose (6 or 60 μg per 1 mL), (ii) strict upper bounds for chromium, aluminum, iron, and other trace metals, (iii) a fluoride or iodine concentration window, and (iv) low pH / acid conditions (including nitric acid) for compatibility with parenteral nutrition use. The core commercial “coverage lever” is the exact trace-element arithmetic per mL (including “no [metal]” plus explicit μg caps) combined with the selection of fluoride versus iodine and selenium source (elemental selenium derived from selenious acid).
This is the kind of patent where design-arounds often fail if the competitor keeps the same selenium dose and uses the same trace-metal control philosophy. A design-around becomes more viable only if it changes one of the numerically defined “switches”: selenium amount, fluoride/iodine window, selenium source, or compliance strategy for the trace-metal limits (chromium, aluminum, iron, and optionally the broader PDL bundle).
What is the exact claim scope of US 11,998,565 (and what does it require per 1 mL)?
Independent claim 1: the minimum required formulation
Claim 1 requires an injectable composition with the following mandatory elements, expressed as per 1 mL:
- Vehicle: water
- Selenium: 6 μg or 60 μg of selenium per 1 mL
- Chromium constraint: “no chromium or chromium in an amount not to exceed 1 μg”
- Aluminum constraint: “no aluminum or aluminum in an amount not to exceed 6 μg”
- Iron constraint: “no iron or iron in an amount up to 10 μg”
- Fluoride constraint: 0.0001 μg to 2.7 μg of fluoride per 1 mL
So claim 1 is already a compound constraint: to infringe, a product must be an injectable composition that hits the selenium dose set (6 or 60 μg/mL), and also stays within the specific trace-metal ceiling structure, and uses the fluoride window.
Dependent claims that “lock in” the core selenium dose
- Claim 2: selenium is 60 μg/mL
- Claim 3: selenium is 6 μg/mL
Dependent claims that refine trace-metal windows
- Claim 4: aluminum 0.0001–0.6 μg/mL
- Claim 5: iron 0.0001–10 μg/mL
- Claim 13: chromium 0.0001–0.25 μg/mL
- Claim 14: aluminum 1 ppm to 6 μg/mL (note that “ppm” language creates interpretive variability, but it is still a narrow numeric cap)
Use and route: parenteral nutrition with adults/pediatrics
- Claim 6: composition suitable for administration to an adult or pediatric patient when added to parenteral nutrition
This is an important boundary condition: it ties the formulation to nutritional infusion workflows, not generic injectables.
Acid/pH constraints
- Claim 8: pH 1.8 to 2.4
- Claim 9: further comprises nitric acid
- Claim 29: claim 15 + nitric acid + pH 1.8–2.4 (reinforces the “low pH trace-metal control” theme)
Selenium source
- Claim 10: selenium is elemental selenium from selenious acid
- Claim 11: claim 2 selenium is elemental selenium from selenious acid
- Claim 12: claim 3 selenium is elemental selenium from selenious acid
Optional iodine substitution
The claims include a parallel fluoride/iodine concept:
- Claim 7: fluoride window replaced by an iodine window (iodine 0.0001–0.2 μg/mL)
- Claim 15: independent-format claim that uses iodine 0.0001–0.2 μg/mL instead of fluoride
In practice, this means a product using iodine at the specified concentration band can fall under separate claim coverage even if it avoids fluoride.
Vial size recitation
- Claim 22: composition in a 1 mL, 2 mL, 3 mL, 5 mL or 10 mL vial
This can matter in enforcement if a competitor ships a different container format.
How much do the “fluoride vs iodine” claims broaden infringement risk?
Fluoride coverage (claim 1 and related)
- Claim 1: fluoride 0.0001–2.7 μg/mL
Dependent coverage also includes:
- Claim 25’s long PDL list includes many metals but does not replace the fluoride/iodine requirement in claim 1 itself. Claim 25 is an additional constraint on permitted daily limits.
Iodine coverage (claim 15 and related)
- Claim 15: iodine 0.0001–0.2 μg/mL
- Claim 17: suitable for adult/pediatric when added to parenteral nutrition
- Claim 18: claim 3 suitable for pediatric or neonatal when added to parenteral nutrition
- Claim 19: selenium from selenious acid
- Claims 20–21: selenium dose fixed to 60 or 6 μg/mL
Key point for infringement scoping: a manufacturer may avoid fluoride-range compliance but still trigger infringement if it uses iodine within the claimed band and hits the selenium dose plus trace-metal constraints.
What does “no chromium / no aluminum / no iron” mean for design-arounds?
Non-detection is not necessarily a safe harbor
The language is “no chromium or chromium ≤ 1 μg” (and analogs for aluminum and iron). That structure means:
- A product with trace chromium above detection but still below the cap can still infringe.
- A product with “no chromium” only helps if chromium is truly absent or below the practical interpretation of “no chromium” (which can turn into evidentiary fights over assay limits and contamination controls).
Most “actionable” variables for legal risk
- Chromium ≤ 1 μg/mL (claim 1) and 0.0001–0.25 μg/mL (claim 13)
- Aluminum ≤ 6 μg/mL (claim 1) and narrower subranges (claims 4, 14)
- Iron ≤ 10 μg/mL (claim 1) and 0.0001–10 μg/mL (claim 5)
A design-around that relaxes trace-metal controls may move out of the caps, but that is commercially constrained because parenteral nutrition and trace metal impurities create safety and stability issues.
What is covered by the “pH 1.8 to 2.4” and nitric acid limitations?
Acid environment is part of the claimed formulation
- Claim 8 locks pH 1.8–2.4
- Claim 9 adds nitric acid
- Claim 29 repeats this combination with claim 15
Infringement consequence: an accused product could meet the selenium and trace-metal numbers but still avoid certain dependent-claim coverage if it is formulated outside the pH window or without nitric acid. However, claim 1 itself does not explicitly require nitric acid or the pH window, so those limitations are strongest for dependent-claim targeting.
Which additional constraints expand the patent’s coverage beyond the “main capsule”?
Silicon impurity and container-material linkage
- Claim 28: glass vial or ampule and silicon impurity ≤ 100 μg/mL
This can matter because trace silicon can leach from glass under specific processing/storage. A competitor using different packaging (or controlling silicon outside the limit) may avoid claim 28 but not necessarily claim 1/15.
Expanded PDL bundle
- Claim 25 provides a permitted daily limits list for many elements (cadmium, lead, arsenic, mercury, cobalt, vanadium, nickel, thallium, gold, palladium, iridium, osmium, rhodium, ruthenium, silver, platinum, lithium, antimony, barium, molybdenum, tin, chromium, aluminum, boron, calcium, iron, potassium, magnesium, sodium, tungsten, silicon, etc.)
Scope implication: claim 25 adds an extensive safety/quality constraint that is harder for a generic formulation to satisfy unless its impurity strategy is aligned to the same daily exposure limits. But it is not clear from the claim text you provided whether claim 25 is drafted as a stand-alone independent claim or as a dependent claim tied to claim 1. Based on your text, it is presented as part of the claim set, so infringement analysis must treat it as an additional optional layer for products whose total daily intake matches the PDL structure.
What are the key “claim arithmetic” scenarios for potential infringement?
Scenario A: selenium 60 μg/mL + fluoride in window + trace-metal caps
A product is at high risk of falling within claim 1 if it has:
- selenium at 60 μg/mL
- fluoride at 0.0001–2.7 μg/mL
- chromium ≤ 1 μg/mL
- aluminum ≤ 6 μg/mL
- iron ≤ 10 μg/mL
- water vehicle
- plus the product is used as parenteral nutrition additive (for claim 6)
Scenario B: selenium 6 μg/mL + iodine in window + trace-metal caps
A product is at high risk of falling within claim 15 if it has:
- selenium at 6 μg/mL
- iodine at 0.0001–0.2 μg/mL
- chromium ≤ 1 μg/mL
- aluminum ≤ 6 μg/mL
- iron ≤ 10 μg/mL
- water vehicle
- plus adult/peds or neonatal suitability constraints for claims 17 and 18
Scenario C: selenium dose matches but container-material silicon exceeds limit
If the competitor’s silicon impurity in glass exceeds 100 μg/mL, it may avoid claim 28 but not automatically avoid claims 1/15 unless the formulation also fails other trace-metal caps.
How many separate “design switches” exist inside US 11,998,565?
Using your claim set, at least these switches can move infringement risk materially:
- Selenium dose: 6 vs 60 μg/mL (claims 1–3, 20–21)
- Fluoride vs iodine: fluoride 0.0001–2.7 μg/mL (claim 1) vs iodine 0.0001–0.2 μg/mL (claim 15)
- Trace-metal caps:
- chromium ≤ 1 μg/mL (claim 1) with tighter subrange (claim 13)
- aluminum ≤ 6 μg/mL (claim 1) with tighter subranges (claims 4, 14, and implied ppm language)
- iron ≤ 10 μg/mL (claim 1) with subrange (claim 5)
- Selenium source: elemental selenium “from selenious acid” (claims 10–12, 19)
- Low pH: pH 1.8–2.4 (claim 8)
- Nitric acid: presence (claim 9 and claim 29)
- Silicon impurity: ≤ 100 μg/mL in glass/ampule (claim 28)
- PDL impurity strategy: meeting the long PDL list (claim 25)
- Container size: 1–10 mL vial formats (claim 22)
A competitor that keeps selenium dose constant but substitutes fluoride with iodine can still fall into a parallel claim set.
What patent landscape issues matter for freedom-to-operate around US 11,998,565?
1) Likely nexus to trace-metal impurity control patents
The claim set is dominated by impurity/contamination limits (chromium, aluminum, iron, and a broad PDL list), plus packaging-derived silicon and pH/acid conditions.
From a landscape standpoint, this typically clusters with:
- formulation/process patents for parenteral trace element additives
- purification and control patents (reducing metal leachables and reagent-derived impurities)
- container and closure compatibility patents (glass leaching controls)
- analytical method/qualification patents for impurity profiling (not shown in your claim list but often paired in this domain)
2) Enforcement posture tends to focus on “product-by-product” impurity assay
Because the claims are numeric at μg/mL resolution, infringement usually turns on:
- batch COAs
- spike/recovery validation
- assay methodology consistency
- per-mL basis conversion from vial fill and dosage administration
- stability data showing the impurities stay within limits through shelf life
3) Secondary formulation and “salt/acid” variants can still infringe
Even if a competitor changes selenium chemical form, the patent may still catch it if selenium is defined as elemental selenium derived from selenious acid. A competitor using a different selenium feedstock may reduce risk for the “from selenious acid” dependent claims, but not for claim 1 unless the main claim 1 requires that source (it does not, based on your provided text). The tightest exposure is for claims 10–12 and 19, which are explicitly selenium source-limited.
When does US 11,998,565 lose exclusivity (term) and how does that interact with generic/parenteral entrants?
No effective dates, filing dates, priority, or expiration dates were provided in your prompt. Without those, it is not possible to compute:
- earliest possible patent expiration
- term adjustments
- pediatric exclusivity interactions (if any)
- or whether terminal disclaimers exist
Since you requested a detailed landscape with hard data, exclusivity timing cannot be produced from the information you supplied.
How strong is the patent estate for these claims (based on claim structure only)?
Strong points
- The independent claim is numeric and composition-based, which narrows the universe of non-infringing products.
- The claim set includes parallel fluoride and iodine embodiments, reducing the probability that a simple substitution avoids coverage.
- Selenium dose is discretized into two options (6 and 60 μg/mL). If the market dose matches those values, the patent is aligned to product reality.
Potential weakening points (from scope mechanics)
- Some “real-world” variations may avoid dependent-claim coverage:
- changing pH outside 1.8–2.4 avoids claims 8/29
- omitting nitric acid avoids claims 9/29
- controlling silicon outside the glass limit avoids claim 28
- If the actual selenium source is not “elemental selenium from selenious acid,” the “from selenious acid” dependent claims may be harder to assert.
What generic entry risks exist if a competitor targets parenteral nutrition selenium?
High-risk if competing products track the same dosing and trace-metal caps
For competitors planning an ANDA-style generic or a reformulation entry, the risk profile is highest if they:
- match selenium dose at 6 or 60 μg/mL
- use fluoride in the 0.0001–2.7 μg/mL window
- keep chromium, aluminum, iron below the claimed maxima
- use glass packaging with silicon ≤ 100 μg/mL (claim 28 can also bite)
- and have formulation conditions consistent with pH 1.8–2.4 and nitric acid (for dependent claims)
Lower-risk design alternatives
A competitor can reduce risk by moving at least one major numeric switch:
- selenium dose to a value outside the 6/60 μg/mL bins
- fluoride out of the 0.0001–2.7 μg/mL window and iodine out of 0.0001–0.2 μg/mL
- relaxing chromium/aluminum/iron limits beyond caps (though safety/quality constraints may block this)
- switching packaging or controlling silicon above the claim 28 cap (again, safety and quality constraints may block this)
Key Takeaways
- US 11,998,565 is a composition patent centered on selenium injectable formulations for parenteral nutrition with tightly defined trace metal impurity ceilings.
- Independent claim 1 covers selenium at 6 or 60 μg/mL plus fluoride 0.0001–2.7 μg/mL and trace limits for chromium ≤ 1 μg/mL, aluminum ≤ 6 μg/mL, iron ≤ 10 μg/mL.
- A parallel branch (claim 15 and dependents) covers the same selenium and trace-metal framework with iodine 0.0001–0.2 μg/mL instead of fluoride.
- The highest enforcement leverage is the numerical “per mL” arithmetic across selenium dose, fluoride/iodine, and trace-metal caps.
- Dependent claims further narrow risk using pH (1.8–2.4), nitric acid, selenium source from selenious acid, vial packaging silicon ≤ 100 μg/mL, and an extensive PDL impurity bundle.
FAQs
-
Does US 11,998,565 cover selenium injectables formulated with iodine instead of fluoride?
Yes. Claim 15 covers injectable compositions with iodine 0.0001–0.2 μg per 1 mL under the same selenium dose and trace-metal cap framework.
-
If a product matches selenium dose but has higher aluminum than 6 μg/mL, does it infringe?
It avoids the aluminum constraint in claim 1’s framework (and thus claim 1/15’s independent scope). Whether it infringes other patents depends on those separate claims not provided here.
-
Can changing pH avoid infringement?
Changing pH can avoid dependent claims requiring pH 1.8–2.4 (claims 8 and 29), but claim 1’s independent scope as provided does not include a pH limitation.
-
Is the silicon impurity limitation limited to glass vials/ampules?
Yes. Claim 28 ties the silicon impurity cap (≤ 100 μg/mL) to glass vial or ampule packaging.
-
What is the strongest single variable to assess during product COA review?
Selenium dose (6 vs 60 μg/mL) and whether fluoride (0.0001–2.7 μg/mL) or iodine (0.0001–0.2 μg/mL) is used, because those switch the independent claim pathway.
References
No references are provided because the prompt includes only the claim text for US 11,998,565 and does not include bibliographic records, prosecution history, priority dates, specification excerpts, or external source citations.
